Abstract
Currently, there is a steady growth antimicrobial resistance (AMP) worldwide. This is especially true now when antibiotic use has become uncontrolled due to its use in COVID-19 treatment regimens. Antibiotics do not have antiviral effect, their appointment is justified only with complicated forms of COVID-19. Moreover, such a massive use antibiotics creates the prerequisites for the formation antibiotic resistance, including among the causative agents of community-acquired infections. Due to the relentless the growth of antibiotic resistance of community-acquired pathogens of respiratory diseases, it becomes necessary to revise approaches to antibacterial therapy (ABT) and assessing the potential use of thiamphenicol for the treatment of community-acquired infections caused by respiratory pathogens.
FGAOU VO «Pervyj MGMU im. I.M. Sechenova» Minzdrava Rossii
FDPO FGAOU VO «Rossijskij nacionalnyj issledovatelskij medicinskij universitet imeni N.I. Pirogova»
FGAOU VO «Pervyj MGMU im. I.M. Sechenova» Minzdrava Rossii
FGAOU VO «Pervyj MGMU im. I.M. Sechenova» Minzdrava Rossii
FGBU «Glavnyj voennyj klinicheskij gospital im. akad. N.N. Burdenko» Minoborony Rossii
NII antimikrobnoj himioterapii FGBOU VO SGMU Minzdrava Rossii, Smolensk, Rossiya
FGAOU VO «Rossijskij nacionalnyj issledovatelskij medicinskij universitet imeni N.I. Pirogova»
FGBOU DPO «Rossijskaya medicinskaya akademiya nepreryvnogo professionalnogo obrazovaniya» Minzdrava Rossii
NII antimikrobnoj himioterapii FGBOU VO SGMU Minzdrava Rossii, Smolensk, Rossiya
OGBUZ «Smolenskaya detskaya oblastnaya klinicheskaya bolnica»
FGAOU VO «Pervyj MGMU im. I.M. Sechenova» Minzdrava Rossii
FGAOU VO «Pervyj MGMU im. I.M. Sechenova» Minzdrava Rossii
FGAOU VO «Pervyj MGMU im. I.M. Sechenova» Minzdrava Rossii
GBUZ MO «Moskovskij oblastnoj nauchno-issledovatelskij klinicheskij institut im. M.F. Vladimirskogo»
FGAOU VO «Pervyj MGMU im. I.M. Sechenova» Minzdrava Rossii
NII antimikrobnoj himioterapii FGBOU VO SGMU Minzdrava Rossii, Smolensk, Rossiya